Not yet recruiting
Acute lymphocytic leukaemia+2
Not yet recruitingA Study of Blinatumomab in Children with Relapsed or Treatment-Resistant B Cell Acute Lymphoblastic Leukemia with Remaining Disease Traces
InvestigationalNo placebo
A Study of Blinatumomab in Children with Relapsed or Treatment-Resistant B Cell Acute Lymphoblastic Leukemia with Remaining Disease Traces
InvestigationalNo placebo
- Disease:Acute lymphocytic leukaemiaAcute lymphocytic leukaemia recurrent+1
- Substances:Blinatumomab
Countries:
France
France- Participants:0–17 years
- Substances:Blinatumomab
- Sponsor:Amgen Inc.
